Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation

Boeckh, 2011, Cytomegalovirus: pathogen, paradigm, and puzzle, J Clin Invest, 121, 1673, 10.1172/JCI45449 Boeckh, 2009, How we treat cytomegalovirus in hematopoietic cell transplant recipients, Blood, 113, 5711, 10.1182/blood-2008-10-143560 de la Camara, 2016, CMV in hematopoietic stem cell transplantation, Mediterr J Hematol Infect Dis, 8, e2016031, 10.4084/mjhid.2016.031 El Chaer, 2016, How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients, Blood, 128, 2624, 10.1182/blood-2016-06-688432 Ljungman, 2011, Cytomegalovirus in hematopoietic stem cell transplant recipients, Hematol Oncol Clin North Am, 25, 151, 10.1016/j.hoc.2010.11.011 Broers, 2000, Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation, Blood, 95, 2240, 10.1182/blood.V95.7.2240 Craddock, 2001, Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis, Br J Haematol, 112, 228, 10.1046/j.1365-2141.2001.02519.x Kollman, 2001, Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age, Blood, 98, 2043, 10.1182/blood.V98.7.2043 Nakamura, 2004, Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure, Biol Blood Marrow Transplant, 10, 49, 10.1016/j.bbmt.2003.08.011 Teira, 2016, Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis, Blood, 127, 2427, 10.1182/blood-2015-11-679639 Kalra, 2016, Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation, Biol Blood Marrow Transplant, 22, 1654, 10.1016/j.bbmt.2016.05.020 Ozdemir, 2007, Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies, Bone Marrow Transplant, 40, 125, 10.1038/sj.bmt.1705699 Komanduri, 2007, Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing, Blood, 110, 4543, 10.1182/blood-2007-05-092130 Boeckh, 2003, Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity, Blood, 101, 407, 10.1182/blood-2002-03-0993 Reusser, 1991, Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease, Blood, 78, 1373, 10.1182/blood.V78.5.1373.1373 Erard, 2015, Reduced mortality of cytomegalovirus pneumonia after hematopoietic cell transplantation due to antiviral therapy and changes in transplantation practices, Clin Infect Dis, 61, 31, 10.1093/cid/civ215 Marr, 2002, Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors, Blood, 100, 4358, 10.1182/blood-2002-05-1496 Nichols, 2002, High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection, J Infect Dis, 185, 273, 10.1086/338624 Green, 2016, Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study, Lancet Haematol, 3, e119, 10.1016/S2352-3026(15)00289-6 Camargo, 2016, Impact of viral load on eradication of cytomegalovirus (CMV) viremia amongst high-risk allogeneic stem cell transplant (SCT) recipients, Open Forum Infect Dis, 3, 2290, 10.1093/ofid/ofw172.1837 Garcia-Vidal, 2008, Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation, Clin Infect Dis, 47, 1041, 10.1086/591969 Thursky, 2004, Risk factors for post-engraftment invasive aspergillosis in allogeneic stem cell transplantation, Bone Marrow Transplant, 34, 115, 10.1038/sj.bmt.1704543 Marr, 2000, Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole, J Infect Dis, 181, 309, 10.1086/315193 Boeckh, 2015, Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial, Ann Intern Med, 162, 1, 10.7326/M13-2729 Gimenez, 2014, Early kinetics of plasma cytomegalovirus DNA load in allogeneic stem cell transplant recipients in the era of highly sensitive real-time PCR assays: does it have any clinical value?, J Clin Microbiol, 52, 654, 10.1128/JCM.02571-13 Gimeno, 2008, Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients, J Clin Microbiol, 46, 3311, 10.1128/JCM.00797-08 Green, 2012, Efficacy of a viral load-based, risk-adapted, preemptive treatment strategy for prevention of cytomegalovirus disease after hematopoietic cell transplantation, Biol Blood Marrow Transplant, 18, 1687, 10.1016/j.bbmt.2012.05.015 Green, 2013, CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia, Blood, 122, 1316, 10.1182/blood-2013-02-487074 Mariotti, 2014, Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 20, 885, 10.1016/j.bbmt.2014.02.015 Milano, 2011, Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients, Blood, 118, 5689, 10.1182/blood-2011-06-361618 Panagou, 2016, Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants, Transplant Infect Dis, 18, 405, 10.1111/tid.12542 Peres, 2010, Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR, BMC Infect Dis, 10, 147, 10.1186/1471-2334-10-147 Solano, 2013, Pre-emptive antiviral therapy for active CMV infection in adult allo-SCT patients guided by plasma CMV DNAemia quantitation using a real-time PCR assay: clinical experience at a single center, Bone Marrow Transplant, 48, 1010, 10.1038/bmt.2012.286 Tan, 2015, Cytomegalovirus load at treatment initiation is predictive of time to resolution of viremia and duration of therapy in hematopoietic cell transplant recipients, J Clin Virol, 69, 179, 10.1016/j.jcv.2015.06.006 Torre-Cisneros, 2010, Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients, Enferm Infecc Microbiol Clin, 28, 6, 10.1016/j.eimc.2009.01.010 Avery, 2010, Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients, Transplant Infect Dis, 12, 489, 10.1111/j.1399-3062.2010.00550.x Marty, 2011, Maribavir and human cytomegalovirus-what happened in the clinical trials and why might the drug have failed?, Curr Opin Virol, 1, 555, 10.1016/j.coviro.2011.10.011 Marty, 2011, Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial, Lancet Infect Dis, 11, 284, 10.1016/S1473-3099(11)70024-X Camargo, 2016, The use of brincidofovir for the treatment of mixed dsDNA viral infection, J Clin Virol, 83, 1, 10.1016/j.jcv.2016.07.021 El-Haddad, 2016, Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience, Antiviral Res, 134, 58, 10.1016/j.antiviral.2016.08.024 Marty, 2013, CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation, N Engl J Med, 369, 1227, 10.1056/NEJMoa1303688 Chemaly, 2014, Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation, N Engl J Med, 370, 1781, 10.1056/NEJMoa1309533 Melendez, 2015, Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus, Infect Drug Resist, 8, 269 La Rosa, 2017, MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults, Blood, 129, 114, 10.1182/blood-2016-07-729756 Wang, 2015, CMVpp65 vaccine enhances the antitumor efficacy of adoptively transferred CD19-redirected CMV-specific T cells, Clin Cancer Res, 21, 2993, 10.1158/1078-0432.CCR-14-2920 Preiksaitis, 2016, Are we there yet? Impact of the First International Standard for Cytomegalovirus DNA on the harmonization of results reported on plasma samples, Clin Infect Dis, 63, 583, 10.1093/cid/ciw370 Ljungman, 2017, Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials, Clin Infect Dis, 64, 87, 10.1093/cid/ciw668 Komanduri, 2001, Direct measurement of CD4+ and CD8+ T-cell responses to CMV in HIV-1-infected subjects, Virology, 279, 459, 10.1006/viro.2000.0697 Sylwester, 2005, Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects, J Exp Med, 202, 673, 10.1084/jem.20050882 Ozdemir, 2002, Cytomegalovirus reactivation following allogeneic stem cell transplantation is associated with the presence of dysfunctional antigen-specific CD8+ T cells, Blood, 100, 3690, 10.1182/blood-2002-05-1387 Krol, 2011, Signature profiles of CMV-specific T-cells in patients with CMV reactivation after hematopoietic SCT, Bone Marrow Transplant, 46, 1089, 10.1038/bmt.2010.261 Kim, 2009, Human late memory CD8+ T cells have a distinct cytokine signature characterized by CC chemokine production without IL-2 production, J Immunol, 183, 6167, 10.4049/jimmunol.0902068 Komanduri, 2013, The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression, Immunol Res, 57, 140, 10.1007/s12026-013-8461-4 Price, 2008, Induction and evolution of cytomegalovirus-specific CD4+ T cell clonotypes in rhesus macaques, J Immunol, 180, 269, 10.4049/jimmunol.180.1.269 Betts, 2006, HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells, Blood, 107, 4781, 10.1182/blood-2005-12-4818 Buggert, 2014, T-bet and Eomes are differentially linked to the exhausted phenotype of CD8+ T cells in HIV infection, PLoS Pathog, 10, e1004251, 10.1371/journal.ppat.1004251 Gasser, 2009, Treatment-dependent loss of polyfunctional CD8+ T-cell responses in HIV-infected kidney transplant recipients is associated with herpesvirus reactivation, Am J Transplant, 9, 794, 10.1111/j.1600-6143.2008.02539.x Gimenez, 2015, Functional patterns of cytomegalovirus (CMV) pp65 and immediate early-1-specific CD8(+) T cells that are associated with protection from and control of CMV DNAemia after allogeneic stem cell transplantation, Transpl Infect Dis, 17, 361, 10.1111/tid.12391 Lilleri, 2008, Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection, Haematologica, 93, 248, 10.3324/haematol.11912 Pelak, 2017, Appearance of CMV specific T-cells predicts fast resolution of viremia post hematopoietic stem cell transplantation, Cytometry B Clin Cytom, 10.1002/cyto.b.21348 Fleming, 2010, Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital, J Med Virol, 82, 433, 10.1002/jmv.21727 Lilleri, 2006, Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipients of allogeneic hematopoietic stem cell transplants, Blood, 108, 1406, 10.1182/blood-2005-11-012864 Waldrop, 1997, Determination of antigen-specific memory/effector CD4+ T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency, J Clin Invest, 99, 1739, 10.1172/JCI119338 Komanduri, 2001, Loss of cytomegalovirus-specific CD4+ T cell responses in human immunodeficiency virus type 1-infected patients with high CD4+ T cell counts and recurrent retinitis, J Infect Dis, 183, 1285, 10.1086/319683 Komanduri, 1998, Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1, Nat Med, 4, 953, 10.1038/nm0898-953